HC Wainwright Reduces Earnings Estimates for Apyx Medical

Apyx Medical Corporation (NASDAQ:APYX) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of Apyx Medical in a report issued on Friday, August 7th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.07) per share for the quarter, down from their prior estimate of ($0.06). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Apyx Medical’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Apyx Medical’s Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.25) EPS.

A number of other research firms have also commented on APYX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Finally, Wall Street Zen cut Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.60.

Apyx Medical Trading Down 14.6%

Shares of NASDAQ APYX opened at $3.46 on Tuesday. The company’s 50 day simple moving average is $4.23 and its 200 day simple moving average is $3.94. Apyx Medical has a fifty-two week low of $1.70 and a fifty-two week high of $5.08. The firm has a market capitalization of $145.74 million, a P/E ratio of -17.30 and a beta of 1.39. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The company had revenue of $13.88 million for the quarter, compared to analyst estimates of $13.18 million.

Institutional Investors Weigh In On Apyx Medical

Hedge funds have recently modified their holdings of the business. Nwam LLC bought a new position in shares of Apyx Medical during the 1st quarter valued at about $47,000. Citadel Advisors LLC bought a new stake in Apyx Medical during the 3rd quarter worth approximately $28,000. Hudson Bay Capital Management LP bought a new stake in Apyx Medical during the 4th quarter worth approximately $73,000. Osaic Holdings Inc. acquired a new stake in Apyx Medical during the 2nd quarter worth approximately $50,000. Finally, Franklin Resources Inc. acquired a new stake in Apyx Medical during the 3rd quarter worth approximately $59,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.